abstract |
The present invention relates to the selection, isolation and purification of proteins that are variable regions, known as VHNAR or vNAR, specific to IgNAR-type immunoglobulin antigen receptors and which originate from Elasmobranchii, the clones from which they derive being called VEGFvNAR V32R and V19, and the respective antibodies being called V32R and V19. The amino acid sequences thereof were elucidated, as were the tertiary structures thereof, and the capacity thereof to neutralize vascular endothelial growth factor (VEGF) activity was determined. During development of the invention, these proteins were optimized for expression in an E.coli production model at industrial level. The invention involves the use of these antibodies in general for treating disorders associated with angiogenesis or neovascularization and, in particular, for treating ophthalmological disorders associated with neovascularization by means of the topical administration thereof. |